NGM Biopharmaceuticals Inc NGM:NASDAQ

Last Price$17.51Cboe Real-Time Last Sale as of 3:45PM ET 8/10/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.27(7.82%)
Bid (Size)$17.50 (100)
Ask (Size)$17.53 (69)
Day Low / High$16.53 - 17.53
Volume526.3 K
 

View Biotechnology IndustryPeer Comparison as of 08/10/2022

 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $17.51
Change: +1.27 (7.82%)
Volume: 526.3 K
3:45PM ET 8/10/2022
 
 

FibroGen Inc ( NASDAQ )

Price: $14.39
Change: +0.27 (1.91%)
Volume: 430.2 K
3:46PM ET 8/10/2022
 
 

Syndax Pharmaceuticals Inc ( NASDAQ )

Price: $23.72
Change: -0.27 (1.13%)
Volume: 428.7 K
3:46PM ET 8/10/2022
 
 

Editas Medicine Inc ( NASDAQ )

Price: $18.49
Change: +0.50 (2.78%)
Volume: 1.1 M
3:47PM ET 8/10/2022
 
 

Chinook Therapeutics Inc ( NASDAQ )

Price: $20.53
Change: +1.04 (5.34%)
Volume: 299.9 K
3:47PM ET 8/10/2022
 

Read more news Recent News

--Jefferies & co Initiates Coverage on NGM Biopharmaceuticals With Buy Rating, $25 Price Target
9:48AM ET 7/20/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Buy: Ngm Biopharmaceuticals
5:04PM ET 6/13/2022 MT Newswires

David V Goeddel, 10% Owner, Director, on June 09, 2022, executed a purchase for 984,161 shares in Ngm Biopharmaceuticals (NGM) for $13,286,174. Following...

Insider Buy: Ngm Biopharmaceuticals
5:18PM ET 6/06/2022 MT Newswires

David V Goeddel, 10% Owner, Director, on June 02, 2022, executed a purchase for 34,200 shares in Ngm Biopharmaceuticals (NGM) for $445,739. Following the...

Insider Buy: Ngm Biopharmaceuticals
5:31PM ET 6/02/2022 MT Newswires

David V Goeddel, 10% Owner, Director, on May 31, 2022, executed a purchase for 153,806 shares in Ngm Biopharmaceuticals (NGM) for $2,069,667. Following the...

Company Profile

Business DescriptionNGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA. View company web site for more details
Address333 Oyster Point Boulevard
South San Francisco, California 94080-7014
Phone+1.650.243.5555
Number of EmployeesN/A
Recent SEC Filing08/04/20228-K
Chief Executive Officer & DirectorDavid J. Woodhouse
President & Chief Financial OfficerSiobhan Nolan Mangini
Director & Chief Scientific OfficerJin Long Chen
Vice President-ResearchHui Tian

Company Highlights

Price Open$16.06
Previous Close$16.24
52 Week Range$10.49 - 27.25
Market Capitalization$1.4 B
Shares Outstanding80.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.73
Beta vs. S&P 500N/A
Revenue$108.7 M
Net Profit Margin-196.39%
Return on Equity-41.79%

Analyst Ratings as of 07/19/2022

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset